Abstract
Background
The diagnosis of sarcomatous transformation of plexiform neurofibromas in Neurofibromatosis-1 (NF 1) is a clinical and radiological challenge. Considerable overlap exists in the clinical and the radiological characteristics between the benign enlarging neurofibromas and their counterparts undergoing malignant changes. Surgical biopsy to rule out suspicious malignant transformation is often a problem in deep seated lesions.
Methods
We, in this paper, explore the clinical utility of FDG-PET in detecting and assessing this life threatening complication of neurofibromas. A case is described with FDG-PET and MRI documentation of such transformation and subsequent histopathological correlation. The case upholds the potential advantages of a FDG-PET over the conventional imaging modalities. A review of the existing literature is also carried out; a total of four published reports on this issue were identified in English literature by searches of Pubmed.
Results and conclusion
FDG-PET appeared a reliable as well as sensitive noninvasive technique that might minimize unnecessary deep surgical biopsy to rule out malignant transformation in cases of NF-1 with features of enlargement of a preexisting peripheral nerve sheath tumour, pain or neurodeficit.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
Barker D, Wright E, Nguyen K et al (1987) Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 236(4805):1100–1102
DeClue JE, Cohen BD, Lowy DR (1991) Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci USA 88(22):9914–9918
Gutmann DH, Collins FS (1993) The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron 10(3):335–343
Wolkenstein P, Freche B, Zeller J, Revuz J (1996) Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. Arch Dermatol 132:1333–1336
Friedman JM, Birch PH (1997) Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 70:138–143
Cotran RS, Kumar V, Robbins SL (1994) Robbins pathologic basis of disease, 5th edn. W.B. Saunders, Philadelphia, pp 1353
National Institutes of Health (1988) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45(5):575–578
DeBella K, Szudek J, Friedman JM (2000) Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 105:608–614
Riccardi VM (1992) Neurofibromatosis. Phenotype, natural history and pathogenesis, 2nd edn. John Hopkins University Press, Baltimore
Seizinger BR (1993) NF 1: a prevalent cause of tumorigenesis in human cancers? Nature Genet 3:97–99
Riccardi VM (1992) Type 1 neurofibromatosis and the pediatric patient. Curr Probl Pediatr 22:66–107
Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J (1992) Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356(6371):663–664
Ferner RE, Lucas JD, Oȁ9Doherty MJ, Hughes RA, Smith MA, Cronin BF et al (2000) Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatr 68(3):353–357
Chander S, Westphal SM, Zak IT, Bloom DA, Zingas AP, Joyrich RN et al (2004) Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med 29(7):415–418
Otsuka H, Graham MM, Kubo A, Nishitani H (2005) FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report. Ann Nucl Med 19(1):55–58
Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M et al (2006) Eur J Nucl Med Mol Imaging 11:1–5 [Epub ahead of print]
Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer section sign G et al (2003) Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 29(6):536–541
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Basu, S., Nair, N. Potential clinical role of FDG-PET in detecting sarcomatous transformation in von Recklinghausen‘s Disease: a case study and review of the literature. J Neurooncol 80, 91–95 (2006). https://doi.org/10.1007/s11060-006-9161-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-006-9161-x